A GPR56-targeted antibody-drug conjugate (ADC) in preclinical study utilizing duocarmycin SA, a DNA minor-groove alkylating agent, demonstrated target-dependent tumor growth inhibition in CRC xenografts and patient-derived organoids with acceptable tolerability (90, 93). Here, ADGRG1 is linked to neoplasm.